Active — Not RecruitingNot Applicable

Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal Cancer

Slovenia30 participantsStarted 2019-06-10

Plain-language summary

This prospective interventional study evaluates the predictive value of tumor mutational burden, liquid biopsy biomarkers (including circulating tumor DNA), angiogenic factors, and dynamic contrast-enhanced magnetic resonance (MR) perfusion imaging in patients with HPV-negative oropharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy. The aim is to improve prediction of treatment response and disease course after treatment, support decision-making regarding optimal therapy, and potentially reduce the number of imaging examinations required during follow-up.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed HPV-negative oropharyngeal squamous cell carcinoma * Planned treatment with concurrent chemoradiotherapy * Ability to undergo MRI examination * Signed informed consent Exclusion Criteria: * HPV-positive oropharyngeal carcinoma * Contraindications for MRI * Severe comorbidities preventing chemoradiotherapy * Pregnancy or breastfeeding * Inability to comply with study procedures

What they're measuring

Predictive Value of Biomarkers and DCE-MRI for Response to Chemoradiotherapy

Timeframe: Up to 6 months after completion of concurrent chemoradiotherapy

Predictive Value of Biomarkers and DCE-MRI for Response to Chemoradiotherapy

Timeframe: Up to 6 months after completion of concurrent chemoradiotherapy

Trial details

NCT IDNCT07407205

SponsorInstitute of Oncology Ljubljana

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Oropharyngeal Squamous Cell Carcinoma trials